House Committees Mark Up Drug Price Negotiation Bills While Centrist Dems Offer Alternative

By John Wilkerson / September 13, 2021 at 12:21 PM
House committees this week mark up Medicare drug price negotiation legislation (H.R. 3) that is supported by the vast majority of House Democrats, while two centrist House Democrats float a less-aggressive approach that would limit Medicare negotiation to Part B off-exclusivity drugs without competition -- House Speaker Nancy Pelosi (D-CA) can only lose a few Democratic votes. Senate Finance Chair Ron Wyden (D-OR) also is expected to release soon drug pricing legislation designed to pass muster with the Senate parliamentarian...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.